Should I buy or sell Globus Medical stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMED shares. View GMED analyst ratings or view top-rated stocks .

What is Globus Medical's stock price target for 2024?

9 analysts have issued 12 month price objectives for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they anticipate the company's share price to reach $66.33 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts .

How have GMED shares performed in 2024?

Globus Medical's stock was trading at $53.29 at the beginning of 2024. Since then, GMED shares have decreased by 2.8% and is now trading at $51.81. View the best growth stocks for 2024 here .

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,760,000 shares, an increase of 32.4% from the March 15th total of 5,860,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 6.7 days. View Globus Medical's Short Interest .

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GMED earnings forecast .

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its earnings results on Tuesday, February, 20th. The medical device company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.01. The medical device company earned $616.53 million during the quarter, compared to analyst estimates of $608.21 million. Globus Medical had a trailing twelve-month return on equity of 8.82% and a net margin of 7.83%. The company's quarterly revenue was up 124.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 EPS.

What ETFs hold Globus Medical's stock?

ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include Motley Fool Mid-Cap Growth ETF (TMFM) , MFAM Small-Cap Growth ETF (MFMS) , Motley Fool Small-Cap Growth ETF (TMFS) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , SPDR S&P Health Care Equipment ETF (XHE) and First Trust Health Care AlphaDEX Fund (FXH) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 2.680-2.700 for the period, compared to the consensus estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com . David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA) , Shopify (SHOP) , CrowdStrike (CRWD) , Okta (OKTA) , Trade Desk (TTD) , Block (SQ) , Tesla (TSLA) , Teladoc Health (TDOC) , Zoom Video Communications (ZM) and Mastercard (MA) .

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bridge City Capital LLC (0.06%), Radnor Capital Management LLC (0.02%), Profit Investment Management LLC (0.02%), Tealwood Asset Management Inc. (0.01%), Banque Cantonale Vaudoise (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Dan Lemaitre , Daniel T Scavilla, Daniel T Scavilla , David D Davidar , David M Demski , James R Tobin, James R Tobin , Keith W Pfeil, Keith W Pfeil , Kelly Huller and Leslie V Norwalk. View institutional ownership trends .

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:GMED

Globus Medical (GMED) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free GMED Stock Alerts

$51.81

+0.14 (+0.27%)

(As of 04/15/2024 ET)

Compare

Today's Range: $51.60
▼
$52.84
50-Day Range: $51.15
▼
$56.43
52-Week Range: $43.38
▼
$62.88

Volume: 757,042 shs
Average Volume: 898,895 shs
Market Capitalization: $7.01 billion

P/E Ratio: 44.28
Dividend Yield: N/A
Price Target: $66.33

Get Globus Medical alerts:

Globus Medical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 28.0% Upside
$66.33 Price Target
Short Interest: Bearish
5.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: 0.74
Based on 6 Articles This Week
Insider Trading: Selling Shares
$550,574 Sold Last Quarter
Proj. Earnings Growth: 21.93%
From $2.69 to $3.28 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

59th out of 928 stocks

Surgical & Medical Instruments Industry

10th out of 99 stocks

3.3

Analyst's Opinion

Consensus Rating
Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Globus Medical has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.73% of the outstanding shares of Globus Medical have been sold short.
Short Interest Ratio / Days to Cover
Globus Medical has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Globus Medical has recently increased by 32.42%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Globus Medical does not currently pay a dividend.
Dividend Growth
Globus Medical does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Globus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.
Environmental Sustainability
The Environmental Impact score for Globus Medical is -0.93.

2.1

News and Social Media Coverage

News Sentiment
Globus Medical has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Globus Medical this week, compared to 4 articles on an average week.
Search Interest
Only 2 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $550,574.00 in company stock.
Percentage Held by Insiders
24.30% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Globus Medical are expected to grow by 21.93% in the coming year, from $2.69 to $3.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Globus Medical is 44.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.93.
Price to Earnings Ratio vs. Sector
The P/E ratio of Globus Medical is 44.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 192.18.
Price to Earnings Growth Ratio
Globus Medical has a PEG Ratio of 1.52. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Globus Medical has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

About Globus Medical Stock (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GMED Stock News Headlines

March 20, 2024 | insidertrades.com

Globus Medical, Inc. (NYSE:GMED) Director Sells $550,574.10 in Stock

April 15, 2024 | americanbankingnews.com

Short Interest in Globus Medical, Inc. (NYSE:GMED) Rises By 32.4%

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 15, 2024 | americanbankingnews.com

Analyzing Globus Medical (NYSE:GMED) and Acutus Medical (NASDAQ:AFIB)

April 12, 2024 | americanbankingnews.com

Globus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 6, 2024 | americanbankingnews.com

Q2 2024 EPS Estimates for Globus Medical, Inc. Raised by Analyst (NYSE:GMED)

March 29, 2024 | finance.yahoo.com

Globus Medical (NYSE:GMED) investors are sitting on a loss of 13% if they invested three years ago

March 24, 2024 | investorplace.com

From Six Figures to Seven: 3 Robotics Stocks Set to Make Millionaires

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 19, 2024 | msn.com

1 'Strong Buy' Growth Stock Wall Street Expects to Soar Around 70%

March 18, 2024 | theglobeandmail.com

Strength in Technology Stocks Leads the Broader Market Higher

March 18, 2024 | theglobeandmail.com

Stocks Rally on Strength in Technology Stocks

March 16, 2024 | nasdaq.com

Globus Medical (GMED) Shares Cross Below 200 DMA

March 16, 2024 | finance.yahoo.com

GMED Apr 2024 57.500 call

March 16, 2024 | finance.yahoo.com

GMED Apr 2024 50.000 put

February 27, 2024 | seekingalpha.com

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

February 25, 2024 | msn.com

Needham sees orthopedics market slowing; favors Enovis, Paragon 28

February 22, 2024 | finance.yahoo.com

Globus Medical Full Year 2023 Earnings: EPS Misses Expectations

February 21, 2024 | realmoney.thestreet.com

Globus Medical price target raised by $3 at Stifel, here's why

February 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)

February 21, 2024 | finance.yahoo.com

Globus Medical, Inc. (NYSE:GMED) Q4 2023 Earnings Call Transcript

February 21, 2024 | finance.yahoo.com

Compared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key Metrics

February 21, 2024 | fool.com

Globus Medical (GMED) Q4 2023 Earnings Call Transcript

February 20, 2024 | benzinga.com

Globus Medical: Q4 Earnings Insights

February 20, 2024 | seekingalpha.com

Globus Medical Non-GAAP EPS of $0.60 misses by $0.01, revenue of $616.53M beats by $8.36M

February 20, 2024 | markets.businessinsider.com

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

February 20, 2024 | finance.yahoo.com

Globus Medical Inc (GMED) Posts Record Sales Amid NuVasive Merger, Despite Net Income Dip

See More Headlines

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NYSE:GMED
CUSIP: 37957720
CIK: 1237831
Web: www.globusmedical.com
Phone: (610) 930-1800
Fax: 610-930-2042
Employees: 5,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $66.33
High Stock Price Target: $86.00
Low Stock Price Target: $53.00
Potential Upside/Downside: +28.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.17
Trailing P/E Ratio: 44.28
Forward P/E Ratio: 19.26
P/E Growth: 1.52
Net Income: $122.87 million
Net Margins: 7.83%
Pretax Margin: 10.55%
Return on Equity: 8.82%
Return on Assets: 7.20%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 4.88
Quick Ratio: 2.72

Sales & Book Value

Annual Sales: $1.02 billion
Price / Sales: 6.87
Cash Flow: $3.62 per share
Price / Cash Flow: 14.32
Book Value: $29.32 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 135,370,000
Free Float: 102,477,000
Market Cap: $7.01 billion
Optionable: Optionable
Beta: 1.08

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. David C. Paul (Age 57)
Co-Founder & Executive Chairman
Comp: $1.09M
Mr. Daniel T. Scavilla (Age 59)
President, CEO & Director
Comp: $1.37M
Mr. Keith W. Pfeil (Age 44)
CFO & COO
Comp: $675.89k
Ms. Kelly G. Huller Esq. (Age 52)
Senior VP, General Counsel & Secretary
Comp: $543.24k
Mr. Brian J. Kearns (Age 57)
Senior Vice President of Business Development & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMED shares.
View GMED analyst ratings or view top-rated stocks.
What is Globus Medical's stock price target for 2024?: 9 analysts have issued 12 month price objectives for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they anticipate the company's share price to reach $66.33 in the next year. This suggests a possible upside of 28.0% from the stock's current price.
View analysts price targets for GMED or view top-rated stocks among Wall Street analysts.
How have GMED shares performed in 2024?: Globus Medical's stock was trading at $53.29 at the beginning of 2024. Since then, GMED shares have decreased by 2.8% and is now trading at $51.81.
View the best growth stocks for 2024 here.
Are investors shorting Globus Medical?: Globus Medical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,760,000 shares, an increase of 32.4% from the March 15th total of 5,860,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 6.7 days.
View Globus Medical's Short Interest.
When is Globus Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GMED earnings forecast.
How were Globus Medical's earnings last quarter?: Globus Medical, Inc. (NYSE:GMED) issued its earnings results on Tuesday, February, 20th. The medical device company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.01. The medical device company earned $616.53 million during the quarter, compared to analyst estimates of $608.21 million. Globus Medical had a trailing twelve-month return on equity of 8.82% and a net margin of 7.83%. The company's quarterly revenue was up 124.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 EPS.

What ETFs hold Globus Medical's stock?: ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include Motley Fool Mid-Cap Growth ETF (TMFM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE) and First Trust Health Care AlphaDEX Fund (FXH).iShares U.S. Medical Devices ETF (IHI).
What guidance has Globus Medical issued on next quarter's earnings?: Globus Medical issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 2.680-2.700 for the period, compared to the consensus estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.
What is David Demski's approval rating as Globus Medical's CEO?: 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Globus Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).
Who are Globus Medical's major shareholders?: Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bridge City Capital LLC (0.06%), Radnor Capital Management LLC (0.02%), Profit Investment Management LLC (0.02%), Tealwood Asset Management Inc. (0.01%), Banque Cantonale Vaudoise (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Leslie V Norwalk.
View institutional ownership trends.
How do I buy shares of Globus Medical?: Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GMED) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial